Menu
Recruiting NCT06417177

Impact of Early Aging and Menopause on the Vascular Responses to Hypoxia

Early Phase I Interventional Aging Menopause Hypoxia Vasodilation

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Placebo, Propranolol, Gemtesa.
Who it may be relevant to
Registry conditions: Aging, Menopause, Hypoxia, Vasodilation. Basic parameters: 18 years — 70 years · Female.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

The purpose of this study is to examine hypoxic vasodilation and the role of beta-adrenergic receptors in younger premenopausal, perimenopausal, and older postmenopausal women.

Interventions

  • Drug Placebo
    Participants will receive a placebo in pill form.
  • Drug Propranolol
    Participants will receive oral propranolol (1 mg/kg).
  • Drug Gemtesa
    Participants will receive oral gemtesa (75 mg).

Primary outcome measures

  • Forearm blood flow [Time frame: Change from baseline to 5 minutes.]

Eligibility criteria

Inclusion criteria

  • Female assigned at birth
  • Pre, peri- or post-menopausal
  • Healthy weight (BMI ≥18 and ≤30 kg/m2)

Exclusion criteria

  • Male (assigned at birth)
  • Pregnancy, breastfeeding
  • Use of hormone replacement therapies
  • Hysterectomy
  • Body mass index >30 kg/m2
  • Diagnosed sleep apnea
  • Current smoking/Nicotine/Drug use
  • Nerve/neurologic disease
  • Cardiovascular, hepatic, renal, respiratory disease
  • Blood pressure ≥140/90 mmHg
  • Diabetes, Polycystic ovarian syndrome
  • Communication barriers
  • Prescription medications
  • Malignant cancer

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Crossover
Masking
Single blind
Primary purpose
Basic science

Study locations

United States · 1 center
  • University of Missouri-Columbia — Columbia

Identifiers

NCT: NCT06417177 · 2100208

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗